ADC$72.01
$72.36
Chart
Performance
Key Stats
AI ADC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAgree Realty Corporation (ADC) presents a compelling investment case driven by its stable REIT model, consistent dividend payouts, and strategic focus on resilient retail sectors. Fundamental analysis indicates strong profitability and a manageable debt load, while thematic tailwinds in e-commerce-resilient retail support long-term growth. Short-term technical indicators suggest a consolidation phase, but the overall trend remains positive.
Thematic
Agree Realty is positioned within the stable, yet evolving, retail real estate sector. Its focus on essential retail and omni-channel tenants provides a degree of resilience against e-commerce headwinds. Thematic alignment is moderate, benefiting from the ongoing transformation of retail but also facing challenges related to specific tenant performance and broader economic sentiment.
Fundamental
Agree Realty demonstrates strong financial health, with robust profitability and a sound balance sheet. Consistent revenue and net income growth, coupled with efficient operations, underscore its fundamental strength. The company maintains a solid dividend payout history, making it attractive for income-focused investors.
Technical
The stock is trading within a defined range, with mixed signals from technical indicators. While the long-term trend appears stable, short-term momentum is neutral, suggesting a period of consolidation or indecision. Key support and resistance levels should be monitored.
| Factor | Score |
|---|---|
| Retail Real Estate Transformation | 80 |
| E-commerce Resilience | 75 |
| Interest Rate Sensitivity | 55 |
| Dividend Sustainability | 70 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 85 |
| Growth | 80 |
| Balance Sheet Health | 80 |
| Cash Flow | 88 |
| Dividend Performance | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Performance
The stock has shown a positive performance over various short-term periods, with 5-day (+3.39%), 1-month (+1.37%), and Year-to-Date (+7.93%) gains, suggesting recent positive momentum.
Attractive Dividend Yield
The dividend yield of 4.06% provides a steady income stream for investors, which is a positive indicator for income-focused strategies.
Bearish Points (7)
High Quarterly P/E Ratios
Recent quarterly P/E ratios (e.g., 178.9 in Q1 2025, 167.9 in Q4 2024) are exceptionally high, suggesting the stock may be significantly overvalued in the short term, potentially leading to volatility.
Inconsistent EPS Surprises
The company has experienced several negative earnings surprises in recent quarters (e.g., -59% in Q2 2025, -4.65% in Q1 2025, -2.65% in Q4 2024), indicating a disconnect between analyst expectations and actual performance.
Calendar
July 2025
31
Ex-Dividend Date
August 2025
1
Next Earnings Date
H: $0.47
A: $0.46
L: $0.44
H: 176.07M
A: 173.07M
L: 167.86M
August 2025
14
Next Dividend Date
Profile
Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of March 31, 2025, the Company owned and operated a portfolio of 2,422 properties, located in all 50 states and containing approximately 50.3 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC".
Seasonals
Price Target
81.87 USD
The 39 analysts offering 1 year price forecasts for ADC have a max estimate of 89.00 and a min estimate of 75.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Acquired Seagen, a leading biotechnology company with multiple approved Antibody-Drug Conjugates (ADCs) including Adcetris, Padcev, and Tivdak, significantly expanding Pfizer's oncology pipeline and market presence in ADCs.
Weight: 98
A global leader in ADC development, notably through its highly successful partnership with AstraZeneca for Enhertu (trastuzumab deruxtecan) and a robust proprietary pipeline of next-generation ADC candidates.
Weight: 97
Co-developer and co-commercializer of the blockbuster ADC Enhertu with Daiichi Sankyo, and actively building its own oncology pipeline with additional ADC programs.
Weight: 95
Pioneered the first approved ADC, Kadcyla (trastuzumab emtansine), and continues to maintain a significant oncology pipeline with ongoing research and development into next-generation ADCs via its Genentech subsidiary.